Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort|
|Citation:||Anaesthesia and Intensive Care, 2012; 40(2):269-274|
|Publisher:||Australian Society of Anaesthetists|
|R. B. Krishnamurthy, R. N. Upton, A. O. Fajumi, S. Lai, C. S. Charlton, R. M. Ousley, A. M. Martinez, H. Mcconnell, S. N. O'connor, J. Ong, P E. Macintyre, M. I. Chapman, G. L. Ludbrook|
|Abstract:||This study aimed to characterise and compare the absorption pharmacokinetics of a single subcutaneous dose of oxycodone in critically ill patients and healthy subjects. Blood samples taken at intervals from two minutes to eight hours after a subcutaneous dose of oxycodone in patients (5 mg) and healthy volunteers (10 mg) were assayed using high performance liquid chromatography. Data were analysed using a non-compartmental approach and presented as mean (SD). Parameters were corrected for dose differences between the groups assuming linear kinetics. Ten patients (eight male, two female) and seven healthy male subjects were included. Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14±0.06 vs. 0.05±0.02 μg/ml (P <0.0001); area under the concentration curve 19.50±9.15 vs. 9.72±2.71 μg/ml*minute (P <0.001) respectively. However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10±18.0 vs. 20.50±16.10 minutes (P=0.81); mean residence time 353±191 vs. 291±80 minutes (P=0.26). Kinetic parameters were less variable in patients than in volunteers. The patients therefore had reduced exposure to subcutaneous oxycodone. This warrants further model-based analysis and experimentation. Dose regimens for subcutaneous oxycodone developed in healthy volunteers cannot be directly translated to critically ill patients.|
|Rights:||Copyright status unknown|
|Appears in Collections:||Aurora harvest 4|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.